Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.

Abstract excerpt

BRAF inhibitors (vemurafenib and dabrafenib) are commonly prescribed in BRAF-mutant metastatic melanoma and allow improvement of the overall survival and progression-free survival. They are, however, accompanied by many adverse effects which mainly affect the skin. We observed on computed tomographic scans in three different patients after 3 months of treatment, the onset of osteosclerotic lesions. In parallel,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Imidazoles
• Share to Indoles
• Share to Osteosclerosis